News

BioAlliance Pharma’s third commercial partnership is potentially worth $12 million to the Paris-based firm, including $1.5 million on signature and a further $1.5 million on first sale in

Through this agreement, Plethora will receive up to $28 million in cash with $15 million payable upon signature and a further $10 million upon first commercial sale of

Gross profit increased to $299.2 million in 2007, or 89.7% of net revenue, compared with $161.1 million, or 88.4% of net revenue, in 2006. On a GAAP basis,

The study results show that SPP100, the first-in-class direct renin inhibitor, has shown clinically meaningful reductions in left ventricular hypertrophy (LVH), a proven predictor of heart disease, that

MIVI III is a Phase IIb, randomized, double-masked, placebo-controlled, dose-ranging trial evaluating three doses of Microplasmin versus placebo in 120 patients scheduled for vitrectomy. The trial is taking

The study is a placebo controlled, double blinded, cross-over design with three doses of CX717 compared to placebo. Depending on the pace of subjects being enrolled, Cortex at

BioMarin established a marketing and distribution agreement with AnGes in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market. AnGes submitted a

The blinded, placebo-controlled trial, which is being conducted at over 10 sites across the US, will enroll up to 48 patients with cystic fibrosis who will receive either

The acquisition brings the total number of pharmacies acquired by the Graymark Healthcare subsidiary to 14 in the 21 months of operations since it was founded in July